The Relationship Between Serum Interleukin-31 Levels and Chronic Kidney Disease-Associated Pruritus in Patients Undergoing Hemodialysis
Keywords:
Hemodialysis, Interleukin-31, 5-D itch scale, visual analog scale (VAS) , Chronic kidney disease-associated pruritus (CKD-aP)Abstract
Background: Chronic kidney disease-associated pruritus (CKD-aP) has been linked to immune dysregulation, including elevated interleukin-31 (IL-31) levels. However, the limited research on serum IL-31 levels in patients with CKD-aP has yielded inconsistent findings due to heterogeneous patient populations and varied assessment methods. This study elucidated the relationship between serum IL-31 levels, CKD-aP, and its severity in patients undergoing routine hemodialysis (HD). Methods: This cross-sectional observational study included patients undergoing HD at Dr. Cipto Mangunkusumo Hospital between April and May 2024. Pruritus was assessed using the visual analog scale (VAS) and 5-D itch scale. Serum IL-31 levels were measured using enzyme-linked immunosorbent assay. Bivariate and multivariate analyses were performed. Results: Among 70 participants (54.3% male; median age, 52.5 years; median HD vintage, 57 months), 35 experienced CKD-aP. The median VAS and 5-D itch scale scores were 5.3 and 13, respectively, indicating moderate itching severity. Patients with CKD-aP had significantly higher serum IL-31 levels than those without CKD-aP (p = 0.05). Receiver operating characteristic analysis showed modest discriminatory ability (area under the curve = 0.64), with a sensitivity of 51.4% and specificity of 74.3% at a cut-off of 173 pg/mL. A significant association was observed between serum IL-31 levels and CKD-aP (p = 0.03). However, no significant correlation was found between IL-31 levels and pruritus severity as measured by the VAS (p = 0.79) or 5-D itch scale (p = 0.44). Conclusion: Serum IL-31 levels were higher in patients with CKD-aP, suggesting its potential association with pruritus. However, its modest diagnostic performance and lack of correlation with itch severity indicate that IL-31 is unlikely to serve as a standalone clinical biomarker and may have a limited role as an adjunctive or exploratory marker.References
Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev. 2020;(12):1–162.
Manns B, Hemmelgarn B, Lillie E, et al. Setting research priorities for patients on or nearing dialysis. Clin J Am Soc Nephrol. 2014;9(10):1813–21.
Rayner HC, Larkina M, Wang M, et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol. 2017;12(12):2000–7.
Aresi G, Rayner HC, Hassan L, et al. Reasons for underreporting of uremic pruritus in people with chronic kidney disease: A qualitative study. J Pain Symptom Manage. 2019;58(4):578–86.
Weisshaar E, Matterne U, Mettang T. How do nephrologists in haemodialysis units consider the symptom of itch: Results of a survey in Germany. Nephrol Dial Transplant. 2009;24(4):1328–30.
Burton JO, Walpen S, Danel S, Schröppel B. Current practices in CKD-associated pruritus: International nephrologist survey. Kidney Int Reports. 2023;8(7):1455–9.
Rehman IU, Lai PSM, Kun LS, Lee LH, Chan KG, Khan TM. Chronic kidney disease-associated pruritus and quality of life in Malaysian patients undergoing hemodialysis. Ther Apher Dial. 2020;24(1):17–25.
Schricker S, Kimmel M. Unravelling the pathophysiology of chronic kidney disease-associated pruritus. Clin Kidney J. 2021;14:I23–I31.
Furue M, Furue M. Interleukin-31 and pruritic skin. J Clin Med. 2021;10(9):1–11.
Ingrasci G, Lipman ZM, Hawash AA, Girolomoni G, Yosipovitch G. The pruritogenic role of the type 2 immune response in diseases associated with chronic itch. Exp Dermatol. 2021;30(9):1208–1217.
Ko MJ, Peng Y Sen, Chen HY, et al. Interleukin-31 is associated with uremic pruritus in patients receiving hemodialysis. J Am Acad Dermatol. 2014;71(6):1151-9.
Haggag MM, Kora MA, Safan MA, Yasien HA, Yousef AM. Study of serum level of interleukin-31 in patients with uremic pruritus. Menoufia Med J. 2020;33(1):257.
Jasim HM, Latif II, Khalid N, Wandi A. Detection of interleukin-2 and interleukin-31 among patients with uremic pruritus. Indian J Forensic Med Toxicol. 2021;15(3):5486–91.
Nazzal Z. Interleukin-31 levels among dialysis patients and its relation with chronic kidney disease-associated pruritus: A cross-sectional study. Res Sq. 2022;1–17.
Świerczyńska K, Krajewski PK, Nowicka-Suszko D, Białynicki-Birula R, Krajewska M, Szepietowski JC. The serum level of IL-31 in patients with chronic kidney disease-associated pruritus: What can we expect? Toxins (Basel). 2022;14(3):1–9.
Zucker I, Yosipovitch G, David M, Gafter U, Boner G. Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: Uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol. 2003;49(5):842–6.
Ständer S, Augustin M, Reich A, et al. Pruritus assessment in clinical trials: Consensus recommendations from the international forum for the study of itch (IFSI) special interest group scoring itch in clinical trials. Acta Derm Venereol. 2013;93(5):509–14.
Narita I, Alchi B, Omori K, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int. 2006;69(9):1626–32.
Elman S, Hynan LS, Gabriel V, Mayo MJ. The 5-D itch scale: A new measure of pruritus. Br J Dermatol. 2010;162(3):587–93.
Wulandani MP, Dachlan AS, Yusharyahya SN. Validity and reliability of 5-D itch scale in Indonesian language on adult and geriatric patients at Dr. Cipto Mangunkusumo Hospital. Adv Sci Lett. 2018;24(9):6994–6998.
Justiz-vaillant AA, Justiz-vaillant AA. ELISA for quantification of IL-31 in human serum. Protocols.io. 2020;6–8.
Kimmel M, Alscher DM, Dunst R, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant. 2006;21(3):749–755.
Feld M, Garcia R, Buddenkotte J, et al. The pruritus- and Th2-associated cytokine IL-31 promotes growth of sensory nerves. J Allergy Clin Immunol. 2016;138(2):500–508.
Agelopoulos K, Pereira MP, Wiegmann H, Ständer S. Cutaneous neuroimmune crosstalk in pruritus. Trends Mol Med. 2022;28(6):452–562.
Asghar MS, Avinash F, Singh M, et al. Associated factors with uremic pruritus in chronic hemodialysis patients: A single-center observational study. Cureus. 2021;13(8):e17559.
Oweis AO, AL-Qarqaz F, Bodoor K, et al. Elevated interleukin 31 serum levels in hemodialysis patients are associated with uremic pruritus. Cytokine. 2021;138:155369.
Pelc M, Koziol M, Szepietowski JC. Expression of IL-31 in uraemic pruritus. Acta Derm Venereol. 2017;97(8):1052.
Datsi A, Steinhoff M, Ahmad F, Alam M, Buddenkotte J. Interleukin-31: The “itchy” cytokine in inflammation and therapy. Allergy Eur J Allergy Clin Immunol. 2021;76(10):2982–2997.
Świerczyńska K, Krajewski P, Reszke R, et al. Uraemic pruritus in dialysis patients (UP-Dial) questionnaire: Creation and validation of the Polish language version. Postep Dermatologii i Alergol. 2022;39(3):538–44.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Acta Medica Indonesiana
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright
The authors who publish in this journal agree to the following requirements:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)
Privacy Statement
The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.
